Massive number of DMF items verged on dropout.

Quite a number of items filed for the DMF seemed to drop out due to insufficient data, and therefore many raw materials would be unable to report in public even though the pharmaceutical bulk drug report system be implemented.

The KFDA Drug Review Division actively reviewed the DMF documentations but still kept it so slow that it would never be completed before the end of this year.

The...